The 2-Year-Old Who Could Be Cured Before Kindergarten

The pediatric approval rests on data from the CLIMB trials in children aged 5 to 11. The results are striking.

In the sickle cell cohort, all eight kids who could be evaluated went a full year or more without a single severe pain crisis. Not a reduction. Not "fewer trips to the ER." Zero. The average crisis-free stretch hit roughly 19 months.

For children with transfusion-dependent beta-thalassemia (a related blood disorder that requires regular blood transfusions to survive), all eight evaluable patients achieved transfusion independence for over a year, with a median duration of about 20 months. These are kids who previously needed transfusions every few weeks just to function.

The FDA then extrapolated those results down to age two, based on the fact that the disease biology and the therapy's mechanism don't change with age. It's the same broken hemoglobin, the same CRISPR fix.

The Catch: Chemo Before the Cure

Casgevy isn't a simple injection. Before receiving their edited cells back, patients undergo myeloablative conditioning with busulfan, a chemotherapy drug that wipes out the existing bone marrow to make room for the new cells. Think of it as demolishing a house before rebuilding it: necessary, but brutal.

In the pediatric trials, the safety issues tracked mostly back to this conditioning step, not the gene-edited cells themselves. Two of 13 children in the thalassemia cohort developed a serious liver complication called veno-occlusive disease. One child died from pneumonia complicated by multi-organ failure, with the death attributed to busulfan toxicity rather than the gene therapy.

That's the tension at the heart of this approval. For a two-year-old who may not yet have frequent pain crises or visible organ damage, families and doctors face a wrenching calculation: accept the known toxicity of chemo conditioning now, or wait and risk the slow accumulation of irreversible harm. There's no easy answer, and experts expect vigorous debate about exactly which toddlers should be treated and when.

A $2.2 Million Question

Casgevy carries a U.S. list price of roughly $2.2 million per patient. That's for a one-time treatment, and it doesn't include the hospitalization, conditioning chemo, and follow-up care that surround it.

For context, the alternative curative option (a bone marrow transplant from a matched donor) requires finding that matched donor in the first place; most kids with sickle cell disease don't have one. The only other approved gene therapy for sickle cell, bluebird bio's Lyfgenia, costs about $3.1 million, carries a black box warning for blood cancers, and hasn't been approved for children under 12.

Sickle cell disease disproportionately affects Black children, a population more likely to be insured through Medicaid. The collision of a multi-million-dollar therapy with an under-resourced payer system creates an access problem that no amount of clinical brilliance can solve on its own. Coverage policies, center-of-excellence networks, and payment models (think installment plans or outcomes-based rebates) will determine whether this approval actually reaches the kids who need it most.

The Bigger Picture: Gene Therapy Grows Up by Getting Younger

Casgevy's age expansion is part of a broader FDA pattern. In December 2025, the agency approved Waskyra, the first gene therapy for Wiskott-Aldrich syndrome, in patients as young as six months. It also cleared Kresladi for severe leukocyte adhesion deficiency in children through accelerated approval. The regulatory playbook is becoming clear: approve in older patients first, then extrapolate downward as safety data accumulates.

The FDA reviewed Casgevy's pediatric expansion in just 53 days, using its new National Priority Voucher pilot program. That kind of speed signals where the agency's priorities lie. Rare pediatric diseases with strong data are getting the express lane.

The Sickle Cell Disease Association of America's Medical Research and Advisory Committee called the approval "exciting" and a major step toward its long-standing goal of a universal cure. That word, "cure," still comes with asterisks; we don't yet know how long the CRISPR edit holds in a growing child, and 15-year follow-up studies are required. But for families who've spent years managing a disease that steals childhoods one hospital visit at a time, the word carries real weight.

A two-year-old treated today could, in theory, start kindergarten without sickle cell disease ever defining their life. That's not just a regulatory milestone. It's a fundamentally different story for a kid who never asked to be sick in the first place.

The FDA Just Overruled Its Own Experts on Moderna's Flu Shot

The FDA's vaccine advisory panel voted 9-0 that Moderna's mRNA flu shot was safe and effective. Then the agency rejected it anyway, on trial design grounds that blindsided the industry. The fallout could reshape how vaccine makers think about U.S. development for years.